Stockwinners Market Radar for July 09, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:57 EDT Twitter plans to pursue legal action to enforce closing of Musk deal - Twitter (TWTR) received a notice of purported termination from Tesla (TSLA) CEO Elon Musk and the Twitter Board issued the following statement in response: "We are committed to closing the transaction on the price and terms agreed upon with Mr. Musk and plan to pursue legal action to enforce the merger agreement. We are confident we will prevail in the Delaware Court of Chancery."

17:27 EDT Twitter slips over 5% to below $34 after Musk terminates deal

17:24 EDT Musk says Twitter failed to provide much of the information he requested - According to a regulatory filing, Tesla (TSLA) founder Elon Musk's legal team sent a letter to Twitter (TWTR) saying that Musk is terminating the merger agreement because Twitter has "still failed to provide much of the data and information" that Musk requested, including: information related to Twitter's process for auditing the inclusion of spam and fake accounts in mDAU; information related to Twitter's process for identifying and suspending spam and fake accounts; daily measures of mDAU fo rthe past eight quarters; board materials related to Twitter's mDAU calculations; and materials related to Twitter's financial condition. "In short, Twitter has not provided information that Mr. Musk has requested for nearly two months notwithstanding his repeated, detailed clarifications intended to simplify Twitter's identification, collection, and disclosure of the most relevant information sought in Mr. Musk's original requests," the letter reads. "While Twitter has provided some information, that information has come with strings attached, use limitations or other artificial formatting features, which has rendered some of the information minimally useful to Mr. Musk and his advisors. For example, when Twitter finally provided access to the eight developer "APIs" first explicitly requested by Mr. Musk in the May 25 Letter, those APIs contained a rate limit lower than what Twitter provides to its largest enterprise customers. Twitter only offered to provide Mr. Musk with the same level of access as some of its customers after we explained that throttling the rate limit prevented Mr. Musk and his advisors from performing the analysis that he wished to conduct in any reasonable period of time. Additionally, those APIs contained an artificial "cap" on the number of queries that Mr. Musk and his team can run regardless of the rate limit-an issue that initially prevented Mr. Musk and his advisors from completing an analysis of the data in any reasonable period of time. Mr. Musk raised this issue as soon as he became aware of it, in the first paragraph of the June 29 Letter: "we have just been informed by our data experts that Twitter has placed an artificial cap on the number of searches our experts can perform with this data, which is now preventing Mr. Musk and his team from doing their analysis." That cap was not removed until July 6, after Mr. Musk demanded its removal for a second time. Based on the foregoing refusal to provide information that Mr. Musk has been requesting since May 9, 2022, Twitter is in breach of Sections 6.4 and 6.11 of the Merger Agreement."

16:58 EDT Itau Unibanco acquires 35% stake in Avenue for R$493M - Itau Unibanco Holding S.A. informs its stockholders and the market that it entered into a share purchase agreement, through its subsidiaries, with Avenue Controle Cayman Ltd and other selling stockholders, providing for the acquisition of control of Avenue Holding Cayman Ltd. After obtaining the required regulatory approvals, Itau Unibanco will initially acquire 35.0% of the total and voting capital of Avenue through a capital contribution of R$160M and a secondary acquisition of shares, totaling approximately R$493M. After 2 years from the closing date of this first tranche, Itau Unibanco will acquire an additional stake of 15.1%, for an amount to be determined based on a predefined multiple of adjusted revenues, achieving the control with 50.1% of the total and voting capital. After 5 years from the closing date of the first tranche, Itau Unibanco will be able to exercise a call option for the remaining equity interest held by the current stockholders of Avenue. Avenue holds a U.S. digital securities broker, incorporated 4 years ago, aimed to democratize the access of Brazilian investors to the international market and currently has over 229,000 active clients, 492,000 accounts enabled and approximately R$6.4B under custody.

16:34 EDT Golden Ocean to construct three Kamsarmax vessels, sell two vessels - Golden Ocean announced that it has entered into agreements for the construction of three high-specification 85,000 dwt ECO-type dual-fuel Kamsarmax vessels, which will be equipped with the latest and most efficient propulsion system. Additionally, the company announces the sale of two Ultramax vessels, Golden Cecilie and Golden Cathrine. The newbuilding vessels will have the same specifications and will be constructed with the same Chinese shipyard group as the seven newbuilding vessels the company previously contracted, providing additional benefits in terms of building supervision and the efficiency gained by operating vessels with similar specifications. The vessels will be delivered to the company in the third quarter of 2024 and the first quarter of 2025. The aggregate sale price of the Ultramax vessels is $63M, and the company expects to record a gain of approximately $22M from sale and receive net cash proceeds of approximately $41M in late Q3/early Q4 2022. The sales proceeds will fund the expected equity portion payable for the three Kamsarmax newbuilding orders placed.

16:18 EDT Virgin Galactic chief legal officer Michelle Kley resigns - According to a regulatory filing, on July 5, 2022, Michelle Kley, Virgin Galactic's Executive Vice President, Chief Legal Officer and Secretary, resigned from the company effective July 19, 2022.

16:01 EDT CBIZ acquires Stinnett & Associates - CBIZ announced that it has acquired Stinnett & Associates of Tulsa, Oklahoma, effective July 1. Founded by Melinda Stinnett in 2001, Stinnett is a professional advisory firm providing internal audit, Sarbanes-Oxley compliance, cybersecurity reviews, business continuity and disaster recovery, and fraud investigations. With offices in Tulsa, Oklahoma City, Dallas, Houston, San Antonio and Denver, Stinnett has 90 employees and approximately $16.4M in annual revenue.

15:51 EDT Exact Sciences 'applauds' proposed CMS change to screening policy - Exact Sciences "applauds" the recently announced Centers for Medicare and Medicaid Services, or CMS, Calendar Year 2023 Physician Fee Schedule proposal, which considers follow-up colonoscopy to an at-home test as a preventive service. If adopted, the rule would eliminate all cost to Medicare patients for a follow-up colonoscopy after a positive at-home colorectal cancer screening test. Additionally, CMS has proposed covering the service for individuals 45 years of age or older who participate in Medicare, which aligns with the previous recommendation from the United States Preventive Services Task Force and the American Cancer Society. The final CMS rule is expected to be published in the fall of this year and take effect on January 1, 2023. Exact Sciences is the maker of Cologuard, an FDA-approved, noninvasive stool-based DNA screening test for adults 45 and older who are at average risk for colon cancer. Kevin Conroy, Chairman and CEO of Exact Sciences, said: "Exact Sciences supports the CMS proposal to encourage wider utilization of non-invasive colorectal cancer screening tests, which has the potential to close the screening gap by reducing barriers to screening, prevention and earlier detection for individuals aged 45 and older."

15:35 EDT Pfizer, BioNTech report FDA approval of sBLA for COVID-19 vaccine for ages 12-15 - Pfizer (PFE) and BioNTech SE (BNTX) announced the U.S. Food and Drug Administration approved the companies' supplemental Biologics License Application, or sBLA, for their COVID-19 vaccine, known as COMIRNATY, to include individuals 12 through 15 years of age. The vaccine was previously made available to this age group in the U.S. under emergency use authorization and to date more than 9 million 12- to 15-year-old adolescents in the U.S. have completed a primary series, the companies stated. Reference Link

13:49 EDT Tremor International up 1% as Betaville highlights rumor mention in The Times - Shares of Tremor International are up 10c, or 1%, to $9.45 after Ben Harrington highlighted earlier this morning in an alert to subscribers of his Betaville blog that The Times' Dominic Walsh noted in a market report about rumors regarding Tremor being a takeover target, which Harrington says have been "circulating in recent weeks." Reference Link

13:19 EDT BHP says appeals court rules Samarco dam suit can proceed - BHP Group is a defendant to a group action claim in the United Kingdom in relation to the Samarco dam failure in November 2015. The group action seeks compensation for individuals, municipalities, private businesses and other institutions in Brazil following the Samarco dam failure. Today, the Court of Appeal decided to allow the appeal. The judgment allows the group action to continue in the U.K. and overturns the earlier decision of the High Court. BHP said it is considering whether to seek permission to appeal the judgment to the U.K. Supreme Court. "The judgment is not a decision in relation to the merits of the claims made in the group action. It is concerned with the preliminary question of whether the group action can continue against BHP in the United Kingdom," the company said in a statement.

13:02 EDT Baker Hughes reports U.S. rig count up 2 to 752 rigs - Baker Hughes reports that the U.S. rig count is up 2 from last week to 752 with oil rigs up 2 to 597, gas rigs unchanged at 153 and miscellaneous rigs unchanged at 2. The U.S. Rig Count is up 273 rigs from last year's count of 479 with oil rigs up 219, gas rigs up 52 and miscellaneous rigs up 2. The U.S. Offshore Rig Count is unchanged at 17, unchanged year-over-year. The Canada Rig Count is up 9 from last week to 175, with oil rigs up 7 to 116, gas rigs up 2 to 59. The Canada Rig Count is up 38 rigs from last year's count of 137, with oil rigs up 28, gas rigs up 11 and miscellaneous rigs down 1.

12:03 EDT Northern Lights Acquisition Corporation (Class A Stock) trading resumes

12:00 EDT Hudbay Minerals falls -6.7% - Hudbay Minerals is down -6.7%, or -27c to $3.79.

12:00 EDT MRC Global rises 13.9% - MRC Global is up 13.9%, or $1.30 to $10.66.

12:00 EDT Seritage Growth Properties rises 72.2% - Seritage Growth Properties is up 72.2%, or $4.39 to $10.47.

11:49 EDT Dr. Reddy's launches Fesoterodine Fumarate Extended-Release Tablets - Dr. Reddy's Laboratories announces the launch of Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz Extended-Release Tablets in the U.S. market following the approval by the U.S. Food and Drug Administration. Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30.

11:06 EDT Pfizer, BioNTech request update for CMA of COVID-19 vaccine in EU - Pfizer (PFE) and BioNTech SE (BNTX) announced that the companies have submitted a variation to the European Medicines Agency, or EMA, requesting to update the Conditional Marketing Authorization, or CMA, in the European Union with data supporting the vaccination of children 6 months to less than 5 years of age, also referred to as 6 months through 4 years of age, with the 3-microgram dose of COMIRNATY COVID-19 vaccine as a three dose series. "The 3-microgram dose was carefully selected as the preferred dose for children under 5 years of age based on safety, tolerability, and immunogenicity data," the companies stated. Reference Link

10:40 EDT Rhino Health USA announces investment by Honeywell - Rhino Health USA announced that Honeywell has finalized terms to invest in and take an ownership interest in Rhino Health to support its U.S. operations for nitrile gloves which serve healthcare, industrial and government customers. "Honeywell is bringing its manufacturing, supply chain and personal protective equipment technical knowledge to help Rhino Health USA accelerate its ramp up and overall production capacity," Rhino said in a statement. The financial terms of the investment were not disclosed.

10:12 EDT Knightscope announces new contract for Autonomous Security Robot - Knightscope announced a new agreement with a storage facility in Napa, California. Knightscope's K5 Autonomous Security Robot will patrol the storage facility to "further enhance the protection offered to tenants that choose to store their belongings with them."

10:04 EDT Alpine 4 Holdings' Quality Circuit Assembly announces plans for CA facility - Alpine 4 Holdings announces its subsidiary, Quality Circuit Assembly will be moving to a new facility in south San Jose, California. QCA anticipates moving to the new facility in mid-late Q1 2023 upon completion of a $2.1M custom build out and installation of $1.4M in new equipment.

10:00 EDT GameStop falls -6.9% - GameStop is down -6.9%, or -$9.36 to $125.76.

10:00 EDT Grove Collaborative falls -16.6% - Grove Collaborative is down -16.6%, or -$1.22 to $6.15.

10:00 EDT MRC Global rises 9.4% - MRC Global is up 9.4%, or 88c to $10.24.

09:50 EDT Cedar Realty Trust completes sale of grocery-anchored portfolio - Cedar Realty Trust announced that it has completed the previously announced sale of a portfolio of 33 grocery-anchored shopping centers and a redevelopment property to a joint venture between a fund managed by DRA Advisors LLC and KPR Centers for total gross proceeds of approximately $879M, including assumed debt. The Company previously sold its Riverview Plaza redevelopment property for gross proceeds of approximately $34M. The completed transactions are the first step in the Company's previously announced sale of the Company's assets and subsequent merger in a series of related all-cash transactions. The final step of the process, expected to be completed within 4-6 weeks, is the merger of the Company with a subsidiary of Wheeler Real Estate Investment Trust (WHLR) in an all-cash transaction that values the Company's remaining assets at $291.3M. Total net proceeds from the transactions, after all expenses, will be distributed to common shareholders upon the completion of the Wheeler merger.

09:47 EDT Grove Collaborative falls -9.4% - Grove Collaborative is down -9.4%, or -69c to $6.68.

09:47 EDT Triton Energy rises 6.2% - Triton Energy is up 6.2%, or $1.94 to $33.45.

09:47 EDT Seritage Growth Properties rises 54.6% - Seritage Growth Properties is up 54.6%, or $3.32 to $9.40.

09:33 EDT Volkswagen Group of America implements EV-enabled Comdata Mastercard - Comdata (FLT) announced a three-year partnership with Volkswagen of America (VWAGY). VWGoA has implemented use of the EV-enabled Comdata Mastercard (MA) and its accompanying features to improve and enhance fleet management operations.

09:26 EDT Ford China sold 120,000 vehicles in Q2 - Ford Motor Company sold approximately 120,000 units in China in the second quarter of 2022, down 22% year-over-year as pandemic-related restrictions and localized lockdowns disrupted business activities for most of the period. Demand for Ford and Lincoln brand vehicles was up significantly in June with the resumption of normal business activities, improved supply chain, and launch of new vehicles. Total sales in June exceeded 50,000 units - up 3% year-over-year and 38% compared to May. Momentum in June was driven by strong passenger vehicle sales. Ford brand passenger vehicle sales exceeded 20,100 units, up 26% year-over-year, including 11,400 SUVs, up 27% compared to the same period last year. Ford brand electric vehicle sales exceeded 1,900 units in the second quarter.

09:16 EDT Pactiv Evergreen launches PlantCarton Life school program - Pactiv Evergreen announced the new PlantCarton Life school program. This program supports Pactiv Evergreen's school milk and juice customers by giving them an interactive, educational resource for their end consumers, school students. The centerpiece of the program is a new website, PlantCartonLife.com. The website offers downloadable carton craft and nature activities for repurposing cartons, gives students the opportunity to contribute content and design ideas that could be featured on a carton, and educates about the sustainable benefits of PlantCarton packaging.

09:05 EDT Mobiquity selected by BlockBusters as data, programmatic ad partner - Mobiquity Technologies announced, it has been selected by BlockBusters, a DeFi software development company, as its data and programmatic advertising provider.

09:03 EDT CVS Health appoints Mandadi as EVP, Chief Data, Digital, Technology Officer - CVS Health (CVS) has appointed Tilak Mandadi as Executive Vice President, EVP, and to the newly created role of Chief Data, Digital and Technology Officer, effective July 25. Mandadi will be responsible for the company's data, digital and technology strategy while overseeing growth and innovation through digital-led, consumer-focused experiences and services. Mandadi joins CVS Health from MGM Resorts International (MGM) where he served as Chief Strategy, Innovation & Technology Officer. Mandadi will become a member of the company's executive leadership team and will report directly to Lynch.

08:46 EDT AgileThought, ExperienceIT partner to accelerate client digital transformation - AgileThought and ExperienceIT announced a strategic partnership to help enterprises discover, design, and deliver on their digital strategic initiatives, at speed through the deployment of Integrated Delivery Squads. The companies said, "This new partnership enables clients to benefit from the combined strengths of the two firms to help them move faster to reach their digital transformation goals. AgileThought can now leverage EIT's breadth and depth of expertise in designing and delivering strategic digital solutions to healthcare and life science organizations; while EIT will be able to accelerate the ability to build scaled delivery teams, by accessing a new global pool of technical talent needed to support them. Together, AgileThought and EIT clients can get expanded support to deliver projects across many disciplines and industries, drawing from AgileThought's proven track record helping enterprises in the financial, professional services, healthcare and life science sectors meet their digital transformation goals."

08:43 EDT iRhythm comments on proposed CMS Medicare Physcian Fee Schedule for 2023 - iRhythm Technologies provided comment on the recently released Centers for Medicare and Medicaid Services Medicare Physician Fee Schedule Proposed Rule for Calendar Year 2023. The Proposed Rule was released on July 7, 2022 and proposes to update the payment rates and other provisions for services furnished on or after January 1, 2023 and reimbursed under the Medicare Physician Fee Schedule. The Proposed Rule is followed by a public comment period which will culminate with CMS' release of a Final Rule, which is expected to be announced by early November for implementation on January 1, 2023. The policies announced in the Proposed Rule are therefore subject to change. The Proposed Rule, with the accompanying addenda, include proposed payment rates for two Category I Current Procedural Terminology code sets related to long term continuous electrocardiogram monitoring and recording that iRhythm uses to seek reimbursement for its Zio XT service. Category I CPT codes 93241 through 93248 are split between two sets of four codes with rates tied to those codes for wear-time of greater than 48 hours and up to 7 days, and greater than 7 days up to 15 days. iRhythm primarily relies on CPT codes 93247 and 93243 to seek reimbursement for its Zio XT service. In the Proposed Rule, CMS proposed relative value units for CPT codes 93247 and 93243 and a Calendar Year 2023 Conversion Factor that, collectively with the Medicare payment reduction and the sequestration under the statutory Pay-As-You-Go, may imply national payment rates of $215 and $204 for CPT codes 93247 and 93243 codes, respectively. Based on the proposed CY 2023 Geographic Practice Cost Index modifiers applicable to the locations of the Company's Medicare-enrolled Independent Diagnostic Testing Facilities in Chicago, IL, Houston, TX and San Francisco, CA, iRhythm estimates the applicable payment rates could range from $218 to $295 for CPT code 93247 and $207 to $280 for CPT code 93243. Using the Proposed Rule's implied rates and based on the Company's current expectations for volume mix across its IDTF locations in CY 2023, iRhythm initially estimated that if the proposed CY 2023 rates had been implemented for CY 2022, the impact to its revenues would have been immaterial to its current full-year 2022 revenue guidance. "We appreciate CMS's evaluation of the cost inputs they have been provided and for their continued focus on establishing National rates for long-term continuous ECG monitoring," said Quentin Blackford, iRhythm's President and CEO. "We will continue to engage with CMS during the open comment period to share relevant information in support of the rule-making process, in anticipation of the release of the Final Rule. Meanwhile, we remain focused

08:37 EDT SciSparc to expand clinical operation to include U.S. site towards SCI-110 trial - SciSparc announced it has started the process of preparing for an Investigational New Drug Application with the U.S. Food and Drug Administration for its Phase IIb clinical trial for SCI-110 in patients suffering from Tourette Syndrome. The work towards an IND submission is intended to open a U.S. clinical site that will take part in the phase IIb trial. Previously, a Phase IIa trial conducted at the same site at Yale University showed that trial patients, which were TS medication-refractory, had a reduction of tic symptoms of 21% across the entire sample. Improvement over time with treatment was also observed when generalized linear models were used to analyze repeated measures data on the Yale Global Tic Severity Scale. In addition, no evidence of adverse events of clinical concern were observed. Based on these positive results, the Company is currently advancing into a phase IIb trial. The objective of this phase IIb randomized, multi-national, multi-center, double-blind, placebo controlled cross-over trial is to evaluate the efficacy, safety and tolerability of SciSparc's proprietary drug candidate SCI-110 in adult patients. The patients will be randomized in a 1:1 ratio to receive either SCI-110 or SCI-110 matched placebo. The primary efficacy objective of the trial will be to assess tic severity change using the most commonly used measure in clinical trials, as a continuous endpoint at week 12 and week 26 of the double-blind phase compared to baseline. The primary safety objective of the trial will be to assess absolute and relative frequencies of serious adverse events for the entire population and separately for the SCI-110 and placebo groups. The Company recently announced it has received the Ethics Committee approval from Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel, which will be the two first sites of the phase IIb trial.

08:35 EDT Acer, Relief announces utility model patent issuance for ACER-001 by CNIPA - Acer Therapeutics (ACER) and its collaboration partner, RELIEF THERAPEUTICS (RLFTF) announced that the China National Intellectual Property Administration issued Electronic Patent Certificate ZL202122004991.9 on May 24, 2022, for Utility Model directed to ACER-001. Specifically, the newly issued patent covers dosage form claims related to ACER-001's polymer coated formulation for oral administration as a potential treatment for urea cycle disorders and Maple Syrup Urine Disease. The newly issued patent has an expiration date of August 24, 2031.

08:32 EDT Alcoa to begin construction on project to raise capabilities at Deschambault - Alcoa announced that construction will soon begin on a project to increase the casting capabilities at its Deschambault smelter in Canada to include standard ingots. The new casting equipment will be constructed in an existing building, with the project fully complete in the first quarter of 2023. The output from the approximately $8M return-seeking capital investment will complement the site's two existing vertical casting pits, which exclusively cast T-bar ingots. Adding standard ingot casting to the site's capabilities will allow greater flexibility for alloying in smaller batches to meet customer needs for value-add products such as foundry alloys for the automotive industry. Each standard ingot weighs approximately 10.5 kilograms.

08:18 EDT SaverOne 2014 reports five new pilot agreements - SaverOne 2014 (SVRE) announced new pilot agreements with some of Israel's leading companies including the Israeli branches of leading global companies, building on the Company's existing strong market traction. The Company has launched several new pilots to install its SaverOne protection system, preventing drivers from distracting and dangerous mobile phone use while driving. These recent pilots include Tempo; Novolog; Flex Storage; Bezeq (BZQIF); and Cellcom. The fleets of these companies total over one thousand vehicles. "We continue to build momentum in expanding our customer base," commented Ori Gilboa, CEO of SaverOne. "We are very pleased with the recent progress, launching new pilots that significantly expand our addressable markets. These pilots are a major step towards commercial agreements and we believe that they are also a demonstration of the success of our vertically focused approach. This approach focuses on verticals such as technicians, heavy delivery, hazardous materials and public transportation. These verticals have unique characteristics which make our solution more relevant, including significant mileage on the road and significantly higher potential impact, should an accident occur." Continued Gilboa, "Furthermore, as part of our global strategy, many of our agreements are with the local Israeli branches of international companies. This, we believe will support our international expansion as we demonstrate the significant value we bring to their Israeli subsidiaries."

08:16 EDT Galiano Gold Gold Fields provides metallurgy, operational update - Galiano Gold (GAU) provides an update on metallurgical test work and plant recoveries at the Asanko Gold Mine, AGM, located in Ghana, West Africa. The AGM is a 50:50 joint venture with Gold Fields (GFI) which is managed and operated by Galiano. As previously announced on February 25, 2022, the Company reported that the AGM experienced lower than expected recoveries in Q1 2022. Subsequent to the announcement, an extensive drilling campaign was completed to provide representative samples for metallurgical testing. Encouraging results have been received from the initial site assessment which determined the cyanide soluble gold content of pulverized intervals via Bulk Leach Extractable Gold technique followed by fire assay of solid residue. During Q2, significant work took place to optimize the AGM's plant performance. The optimizations resulted in recoveries increasing quarter on quarter, averaging 84% in Q2. Consequently, gold production was positively impacted with preliminary production of approximately 50,000 ounces during the quarter.

08:14 EDT Vita Coco announces World's Biggest Coconut roadside experience - Vita Coco announced the World's Biggest Coconut roadside experience popping up in Dallas from Friday, July 22 until Sunday, July 24. The giant inflatable coconut will be visible throughout the neighborhood, a nod to "Everything is Bigger in Texas." Standing over three stories tall, the giant inflatable coconut will be visible throughout the neighborhood. In addition to the coconut, the roadside experience features local food trucks, outdoor games, and the opportunity for visitors to hydrate with products from Vita Coco. The experience will highlight the brand's first juice beverage offering, Vita Coco Coconut Juice.

08:09 EDT FOREWARN partners with Southwest Multiple Listing Service - FOREWARN announced that Southwest Multiple Listing Service has contracted to make FOREWARN services available for the 4,000+ REALTOR members it serves throughout Central New Mexico, including Bernalillo, Valencia, Sandoval, Torrance, parts of Socorro, and Santa Fe Counties to promote proactive real estate agent safety.

08:08 EDT GreenPower Motor acquires Lion Truck Body - GreenPower Motor Company announces the acquisition of Lion Truck Body. "Leveraging upon Lion Truck Body's years of expertise, the deal will provide robust potential for GreenPower's EV Star truck customers," the company said. "Our customers seek energy-efficient solutions that maximizes cargo capacity and delivery range. Lion Truck Body's expertise in bodybuilding with our EV Star CC addresses these requirements directly," said Brendan Riley, President of GreenPower. "This acquisition provides our EV Star truck customers with many options for any number of body types required to meet their business needs with greater speed to market - completed in a few weeks versus taking months. We have been working with Lion Truck Body for some time to make lightweight and efficient truck bodies for our EV Star as well as other models of electric trucks. We are pleased to add the Lion Truck Body franchise into our business." GreenPower and Lion Truck Body entered into an asset purchase agreement under which GreenPower has purchased the assets of the business through a wholly owned subsidiary. GreenPower's purchase of Lion Truck Body is comprised of upfront cash payments totaling $215,000, the assumption of certain liabilities totaling approximately $1.45M, and remaining cash payments of up to $25,000, which remain subject to customary adjustments and other post-closing conditions.

08:06 EDT Kanen Wealth urges Build-A-Bear to 'take transformative action immediately' - The following is a statement issued by Dave Kanen, who serves as Managing Director at Kanen Wealth Management: "Kanen Wealth Management and its affiliates are one of the largest shareholders of Build-A-Bear with a 6.5% stake. We believe the company has an extraordinary opportunity to allocate capital in a way that would create significant value for long term shareholders. We have obtained a professional valuation of the company's owned distribution center which suggests a valuation in a sale lease back of at least $31M and an associated lease expense of ~$1.8M. BBW has the opportunity to sell this asset at ~17.2x earnings and repurchase stock at ~3.2x EBITDA, this would be accretive to earnings per share by ~11%. Furthermore, BBW has significant net cash today and is likely to improve to ~$75M in net cash within the next 6 months. Meaning at a 15% premium to today's price, BBW could retire 6.2M shares just by monetizing its distribution center and returning its year end net cash to shareholders via share repurchases. This 6.2M share repurchase would allow shareholders to own 67% more of the BBW businessand be enormously accretive. Importantly, this would leave BBW with a very strong balance sheet, continued ability to invest all future FCF back into the business, and in our opinion is unequivocally the best way the company can allocate its capital to create value...This board owes shareholders an explanation as to why the company is not acting on this opportunity, if there is a capital allocation path that creates more value with less risk, then the management and the board should enlighten shareholders - the owners of the business. Regarding M&A, we likely cannot buy a business as good as our own for less than 3.2x EBITDA and one that carries no integration risk like that of share repurchases. Does it make sense to hoard $75-100M+ in net cash on the balance sheet while ignoring the value creation highlighted above? The majority of the members of the BBW board own a minimal number of shares and we estimate that 95%+ of the shares owned by the board have been granted as opposed to putting real skin in the game. We find it disturbing that directors with very little skin in the game Lord their "ill-advised authority" over shareholders who are the TRUE OWNERS of the company. Both management and the board are saying "GOOD ENOUGH FOR THEE BUT NOT ME" by your continued dumping of shares. It's grotesque and abusive! If an investor looks at a chart of the stock over the last 8 years under Sharon John's tenure, there is little to show. I would call it mediocrity. In our opinion, the CEO SHARON JOHN IS NOT NUMBERED amongst the winners when it comes to shareholder returns which is the ultimate scorecard and mandate. As a result, in our opinion, she's a 5 on a scale of 1-10. We have made numerous recommendations over the past 3 years, both while I was a director and investor. Some of them are: 1) a meaningful entry into the Pet toy market 2) a 3rd party retailer relationship with a partner that has 100's of locations for a "store within a store" such as Chuck E. Cheese 3) Sale lease back with a large stock tender and 4) partnerships with elementary education providers. In my opinion, it seems as though our CEO cannot execute an idea that's not her own. Rather, exhibiting signs of egotism at the expense of results and to the detriment of shareholders. We are calling for an end to this seemingly childish behavior, or if this is a mere coincidence, to "get after it"! Thus far, your growth initiatives are "incrementalist" at best and not transformative. In summary, our message for management and the board is to take transformative action immediately as we have laid out above. We welcome other shareholders along with us, to express their views, and equally hold BBW management and the board accountable."

08:05 EDT Gan Limited repurchases 303,000 shares for $3.30 per share - Gan Limited announced that it has repurchased approximately 303,000 shares on the open market under its existing share repurchase authorization for approximately $1M, or an average cost of $3.30 per share. There is approximately $4M remaining under the current authorization, which expires November 30.

08:02 EDT Horizon Therapeutics announces FDA approval of Krystexxa sBLA - Horizon Therapeutics announced that the FDA has approved the supplemental biologics license application, or sBLA, expanding the labeling to include Krystexxa injection co-administered with methotrexate, which will help more people with uncontrolled gout achieve a complete response to therapy.

07:54 EDT Berkshire Hathaway increases Occidental Petroleum stake by over 12M shares - In a regulatory filing, Warren Buffett's Berkshire Hathaway (BRK.A) disclosed that it purchased 12,042,470 additional shares of Occidental Petroleum (OXY) in a series of transactions over July 5 and 6 at prices ranging from $56.72 to $57.715 with a total transaction size of about $697.78M. Berkshire Hathaway now holds 18.7% of the energy company's stock after buying the 12 million shares on Tuesday and Wednesday. In pre-market trading, Occidental shares are up $1.05, or 2%, to $62.52.

07:44 EDT Athersys terminates equity purchase agreement with Aspire Capital - Athersys announced that its equity purchase agreement with Aspire Capital has been terminated. The company continues to evaluate alternative financing options to support continuing operations. After several discussions with Aspire Capital, Athersys received notice on July 6 of termination of the equity purchase agreement, effective immediately. The equity purchase agreement had been in place since May 12. In addition, while the company searches for a permanent CFO, the company has designated Camardo as the company's principal financial officer and principal accounting officer. Camardo will not receive any additional compensation or benefits in connection with this designation.

07:33 EDT Ascend Wellness announces share purchase made by independent directors - Ascend Wellness announced that Directors, Emily Paxhia, Scott Swid, and Joseph Hinrichs, each made individual purchases of Class A Common Shares "Shares" in the open market totaling 60,352 shares between July 5th and July 6th. This follows an announcement by AWH that Abner Kurtin, CEO, Chairman, and Founder, and Frank Perullo, President and Co-Founder, made purchases of AWH Shares earlier this week. "Although the fundamentals remain dislocated from valuations, the Board is confident in the trajectory of the Company and the industry as a whole and remains dedicated to supporting Ascend," said Emily Paxhia, Lead Independent Director for Ascend Wellness Holdings.

07:33 EDT Innovid announces change to its board of directors - Innovid (CTV) announced changes in its board of directors. Steven Cakebread has resigned for personal reasons and Brian Hughes has joined as a member of the Board to serve on the Audit Committee of the Board as Audit Committee Chair. Hughes was elected as a Class I director of the Company for a term expiring at the annual meeting of shareholders in 2025 or until his earlier death, resignation or removal. Hughes currently serves as a Director of Bentley Systems (BSY), CompoSecure (CMPO) and Omnilit Acquisition (OLITU).

07:09 EDT Regenxbio announces enrollment complete in cohort 5 of Phase II AAVIATE trial - REGENXBIO announced it has completed enrollment in Cohort 5 of the Phase II AAVIATE trial of RGX-314 for the treatment of wet age-related macular degeneration using in-office suprachoroidal delivery. "We are encouraged by the excellent progress we have made advancing RGX-314 suprachoroidal delivery in both our AAVIATE and ALTITUDE(TM) trials for the treatment of wet AMD and diabetic retinopathy," said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. "RGX-314, has the potential through delivery to the suprachoroidal space to offer the millions of patients facing vision loss from these retinal diseases with a one-time, in-office treatment option. We plan to present additional suprachoroidal data this year."

07:07 EDT Signify Health to wind down ECS segment, expects impact in 2023 - Signify Health announced that it is winding down its Episodes of Care Services, or ECS, segment in order to focus on its Home and Community Services, or HCS, business and recent Caravan Health acquisition. The company is exiting CMS' Bundled Payments for Care Improvement-Advanced, or BPCI-A, program in light of the newly released CMS retrospective trend calculations that lowered target prices for episodes, thereby reducing the opportunity for savings. This strategic and timely decision allows the company to invest more to drive the future growth and diversification of the HCS and Caravan Health businesses supporting the needs of health plans and providers in total cost of care contracts, where they take responsibility for the cost of a patient's healthcare over the course of a year. The company anticipates these changes will have a positive impact on 2023 earnings, and will provide additional guidance in its Q2 earnings report in early August. The company's timing and decision to terminate its participation in the BPCI-A program is driven by recent policies implemented by the Center for Medicare & Medicaid Innovation, or CMMI, affecting BPCI-A pricing that the company and its clients believe have rendered the program unsustainable. The BPCI-A pricing methodology has changed repeatedly over the years and has recently included the imposition of a retrospective adjustment that is not based on publicly available data, cannot be accurately forecasted, and is known only long after a performance period has ended, making it impossible to take real-time action. The company is currently in the process of contesting the most recent pricing calculations through CMMI's standard appeals process and advocating for CMMI to offer providers immediate relief. The Caravan Health business is not impacted by these changes. Caravan Health was acquired by Signify Health in March for its strong capabilities in enabling providers and accountable care organizations, or ACOs, to excel in population health management and value-based payment programs. Since the acquisition, this business has continued to outperform as clients align themselves with CMS' goal of having all Medicare beneficiaries in an accountable relationship with their health care provider by 2030, and recognize the benefits of leveraging Signify's diverse capabilities in managing the cost for all of the care provided to a patient. This includes the company's post-acute and transition to home capabilities, as well as key services from its HCS segment, such as the ability to reach patients in their home in order to better manage their care, which the company believes will result in incremental savings in 2023. The company currently estimates that restructuring charges for severance and employee-related costs will be approximately $25-$35M. There are approximately $85M of annualized direct ECS costs which will be eliminated. In addition, there are approximately $60M of annualized shared costs currently allocated to the ECS segment, of which the company expects to eliminate approximately $30M-35M in annualized costs by the end of 2022 as it winds down the BPCI-A program. "These cost reductions will be positive for unlocking future earnings given projections for ECS performance, where future losses would have exceeded the stranded costs," said Steve Senneff, Signify Health's president, chief financial and administrative officer. "We are de-risking Signify's financial profile and driving capital allocation within the Company to support future growth and create more visibility, increased margins, and stronger free cash flow going forward."

07:04 EDT Annexon announces $130M private placement financing - Annexon announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $130M, before deducting placement agent fees and other expenses. The private placement was led by Redmile Group, LLC, with participation by Adage Capital Partners LP, Bain Capital Life Sciences, Driehaus Capital Management, Fairmount, Satter Medical Technology Partners and Venrock Healthcare Capital Partners. In the private placement, Annexon is selling 9,013,834 shares of common stock, pre-funded warrants to purchase up to 24,696,206 shares of common stock and accompanying warrants to purchase up to 8,427,508 shares of common stock, at a combined price of $3.871250 per share of common stock and accompanying common warrant and $3.870250 per pre-funded warrant and accompanying common warrant. Each pre-funded warrant will have an exercise price of $0.001 per share of common stock, will be exercisable immediately and will be exercisable until exercised in full. The accompanying common warrants will have an exercise price of $5.806875 per share of common stock, will be immediately exercisable and expire on June 30, 2025. The private placement is expected to close on July 11, 2022, subject to the satisfaction of customary closing conditions. The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the "Minimum Price" requirement. Jefferies and Cowen are acting as joint placement agents for the private placement.

07:03 EDT Optinose announces additional results from ReOpen2 trial - Optinose announced additional results from the ReOpen trial program evaluating XHANCE for treatment of patients with chronic sinusitis. XHANCE nasal spray is a drug-device combination product combining its proprietary Exhalation Delivery System designed to uniquely deliver drug high and deep in nasal passages with an anti-inflammatory drug. These pre-planned secondary analyses of data from the ReOpen2 trial as well as pooled data from both ReOpen1 and ReOpen2 found that patients using XHANCE in these trials experienced a spectrum of benefits on symptoms and quality of life, as well improvement in objective measures of disease, relative to patients receiving a placebo comparator. As previously disclosed, both co-primary endpoints in ReOpen2 showed significant improvement among patients treated with XHANCE versus placebo comparator, including combined symptom score at 4 weeks and average of percentages of opacified volume at 24 weeks. In pre-planned, exploratory, secondary analyses of ReOpen2, patients treated with XHANCE were also found to have larger improvements than patients receiving placebo comparator at the 4-week time point on each of the four individual defining symptoms of chronic rhinosinusitis, including congestion/obstruction, rhinorrhea, facial pain or pressure, and loss of sense of smell. Pre-planned secondary analyses also revealed greater improvement on the sinonasal outcomes test, a commonly used measure of symptoms, quality of life, and functioning in chronic rhinosinusitis, at week 24 for patients receiving XHANCE then placebo comparator. Nominal p-values for the differences between the group of patients receiving XHANCE and the group of patients receiving placebo were less than 0.05 on each of these measures. Many people with chronic rhinosinusitis have tried and are frustrated with standard nasal steroid sprays. To inform possible differences in response of patients previously using a standard nasal steroid spray, a pre-planned analysis of pooled data from ReOpen1 and ReOpen2 assessed symptom improvement for patients entering the trials with at least moderate symptoms despite reporting use of a standard nasal steroid spray. For this subgroup, patients receiving XHANCE improved more from baseline than patients receiving placebo comparator. Additionally, a pooled analysis was performed to assess change in CT scans, measured by APOV at week 24, for the subgroup of patients receiving XHANCE who had chronic sinusitis without nasal polyps. Compared to patients treated with placebo comparator, XHANCE treatment produced greater reduction in sinus opacification in this subgroup. Differences between active and placebo in the groups receiving one or two sprays per nostril twice daily were similar and nominally statistically significant. The safety profile and tolerability of XHANCE in these trials were consistent with its currently labelled safety profile. In pooled data from both trials inclusive of both dose groups, adverse events occurring at a rate of more than 3% in patients receiving XHANCE that were also more common than in the group receiving the EDS-placebo were epistaxis, COVID-19, nasopharyngitis, and headache.

06:53 EDT Endeavour Silver reports Q2 production 1,359,207 silver oz, 9,289 gold oz - Endeavour Silver reported second quarter 2022 production of 1,359,207 silver ounces and 9,289 gold oz, for silver equivalent production of 2.1 million oz. Production continues to outpace the 2022 production guidance of 6.7-7.6 million silver equivalent ounces, totaling 4.1 million AgEq oz for the six months ended June 30, 2022. "Amid ongoing turmoil in the markets due to supply constraints, continued inflation concerns, and uncertainty from the raising of interest rates from historical lows, we had another solid quarter of production" stated Dan Dickson, CEO. "Despite the current macro trends, the Company and precious metals outlook remains optimistic. Given our positive view for short-term precious metal prices, we are comfortable holding back bullion inventory over the quarter for future sale. First half production results exceeded plan, so we are well positioned to exceed our guidance for the year. The exceptional ore grades at Guanacevi have put us in this position. While it's has been gratifying to see grades reach new highs, we expect grades to align with or be slightly above plan for the second half of the year."

06:31 EDT Aerie Pharmaceuticals announces employee inducement grant - Aerie Pharmaceuticals announced that the compensation committee of Aerie Pharmaceutical's board of directors granted one new employee an award totaling 16,900 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date. This award was made outside of Aerie's stockholder-approved equity incentive plan and was approved by the Company's independent directors as an inducement material to the employee entering into employment with the Company in reliance on Nasdaq Listing Rule 5635(c)(4), which requires this public announcement.

06:07 EDT Tritium appoints Adam Walker to board of directors - Tritium DCFC announced the appointment of Adam Walker to the Company's Board of Directors and to the position of Chairman of the Company's Audit Committee. alker has extensive experience as a corporate leader, most recently with IHS Towers, one of the world's largest telecommunications infrastructure providers, as Executive Vice President and CFO.

06:05 EDT ChipMOS reports Q2 revenue $230.4M vs. $234.8M last year, up 28.2% - Reports June revenue $71M vs. $80.6M last year.

06:02 EDT NewAge CFO Kevin Manion departs - NewAge announced that Kevin Manion, CFO, departed the Company as of July 1, 2022. Lawrence Perkins, who along with his firm SierraConstellation Partners LLC have been engaged to provide Chief Restructuring Officer and other services to the Company, will assume the role of the Company's principal financial officer on an interim basis. Mr. Perkins currently serves as the Company's CRO and advises the Company with respect to, among other things, assistance with the preparation of financial information, stakeholder communication and evaluation of cash flow generation capabilities.

05:47 EDT ADC Therapeutics licenses loncastuximab tesirine to Sobi - Sobi announced an exclusive license agreement with ADC Therapeutics to develop and commercialize loncastuximab tesirine for use in haematology and other indications of large unmet medical need in Europe and most international markets. Loncastuximab tesirine is an antibody-drug conjugate, or ADC, against CD19, a protein expressed on the surface of B cells. It is currently approved in the US for adult patients with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, after two or more lines of systemic therapy. The medicine has orphan drug designation in the EU and is under regulatory review with a decision anticipated in the first quarter of 2023. The license agreement for loncastuximab tesirine aims at augmenting Sobi's presence in orphan diseases within haematology, one of Sobi's two main disease areas. The medicine will expand Sobi's offering to patients with debilitating orphan diseases in haematology and is anticipated to be made commercially available alongside other Sobi haematology medicines, including Doptelet.